In-Vitro Diagnostics Market (IVD) in China: Company Analysis and 2022 Forecasts Research Report

Latest report on In-Vitro Diagnostics Industry of 100 pages now added by a leading business intelligence provider to MarketReportsOnline.com database.

This is the 2nd edition report on China IVD Market. The report titled "China In-Vitro Diagnostics (IVD) Market, Company Analysis & Forecast to 2022" studies in detail the China IVD Market - Application Segment Wise, Company Sales, Registration & Regulatory Status in China IVD & Driving Factors and Challenges for China IVD Market.

Complete report available at http://www.marketreportsonline.com/594845.html.

Company Coverage of China In-Vitro Diagnostics (IVD) Market: Roche Diagnostic, Abbott Laboratories, Sysmex Corporation, Mindray Medical International Limited & Shanghai Kehua Bio-Engineering Co. Ltd.

China In-Vitro Diagnostics (IVD) market is likely to more than triple by 2022 from its current level in 2016. China represents one of the largest clinical laboratory markets in the Asia-Pacific region, and the fastest growing among the top ten IVD country markets. With an aging population, a rapidly growing middle class and a government encouraging preventive care, China IVD market is slated to show substantial growth in the future. China's quickly aging population means the country is experiencing an explosion of chronic conditions such as diabetes, heart disease and cancer.

All of these conditions can be diagnosed and monitored using IVD products. Further, the average Chinese consumer is now willing and able to pay more for healthcare than a decade years ago. Hence, China has the potential for more dramatic growth in the future.

China In-Vitro Diagnostics Market Segment Wise Analysis: Immunoassay is the leading segment in China IVD market. Immunoassay is likely to maintain its dominant position in the forecasting period as well. Clinical Chemistry holds the 2nd position in China IVD market being followed by Molecular Testing. SMBG market accounted for XXX percent market share in 2016. Microbiology and Hematology segments are competing closely with each other to grab maximum share of the pie.

Order a copy of this China In-Vitro Diagnostics (IVD) Market research report at http://www.marketreportsonline.com/contacts/purchase.php?name=594845.

China IVD Market Company Analysis: In China IVD market, Roche Diagnostics is the leader with XXX percent market share in 2016. Sysmex Corporation and Mindary Medical are other top two players in the China IVD market. At present, many local players are present in China IVD market and their combined market share was XXX percent in 2016.

China IVD Market - 8 Application Segments Covered
1. Clinical Chemistry Market
2. Immunoassay Market
3. Hematology Market
4. Coagulation Market
5. Microbiology Market
6. Molecular Testing Market
7. Self Monitoring of Blood Glucose (SMBG) Market
8. Point of Care Testing (POCT) Market

Major Points from Table of Contents:
1. Executive Summary
2. China IVD Market and Market Share Analysis (2007 - 2022)
3. China IVD - Segments Wise Market and Forecast (2007 - 2022)
4. Development Environment of Chinese IVD Industry
5. Profile of In-vitro Diagnostic Reagents Registration Control
6. Registration for In Vitro Diagnostic Reagents in China
7. China IVD Market - Company Wise Sales Analysis (2010 - 2022)
8. Profiles of Select Private Clinical Labs and Diagnostic Services Companies
9. China IVD Industry Drivers
10. China IVD Industry Challenge

Explore more related reports on healthcare market at http://www.marketreportsonline.com/cat/healthcare-market-research.html.

About Us:
MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Contact Us:
Ritesh Tiwari
2nd Floor, Metropole,
Next to Inox Theatre,
Bund Garden Road,
Pune - 411001.
Maharashtra, India.
Tel: + 1 888 391 5441
E-mail: sales@marketreportsonline.com

This release was published on openPR.